The global biological safety testing market, which was valued at USD 4.32 billion in 2022, is projected to reach USD 12.98 billion by 2032, with a compound annual growth rate (CAGR) of 13% throughout the forecast period. The growth of biologics and biosimilars in the pharmaceutical and biotechnology industries is a significant factor contributing to the increasing market revenue. The demand for...